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| INTRODUCTION
thatcanbecorrectedbyreducinglowdensitylipoproteincholesterol(LDL-C)levels.Ithasbeenshownthat decreasingLDL-ClevelsisaneffectivewaytolowerCVrisk. 5, 6 TheSixthJointTaskForceoftheEuropeanSocietyofCardiology proposes LDL-C goals that are dependent on overall CVE risk; for patientswithveryhigh,highandmoderateCVErisk,LDL-Cgoalsof <70mg/dL(<1.8mmol/L),<100mg/dL(<2.6mmol/L)and<115mg/ dL (<3.0mmol/L), respectively, are recommended. In order to achieve these goals,
European guidelines for the management of hypercholesterolaemia recommend lifestyle changes such as dietary modifications and weight loss as initial measures.
3,7
Even after dietary adjustments, however, LDL-Cgoalsareoftennotattained. 8, 9 For patients who have continuallyelevatedLDL-Clevels,statinsarerecommendedasafirst-linetherapeuticintervention,andasasecondline,thecholesterolabsorption inhibitor ezetimibe and bile sequestrants can be added to statins. 3, 7 However, these therapies may not be sufficient in all patients. In a studyin2012,almosthalfofpatientswithhypercholesterolaemiain
EuropeandCanadadidnotachievetheirLDL-Cgoals,despitereceiving statins. 10 Thismaybeduetothefactthatsomepatientsarestatinintolerantandstoptakingtheirmedication.Additionally,somepatients mayhaveveryhighbaselineLDL-Cconcentrationsandthemaximum tolerated statin dose is insufficient to reduce LDL-C to goal levels; therefore, alternative lipid-lowering therapies (LLTs) may be needed incertainindividuals.Long-termpersistencewithstatinsisimportant for efficacy 11 ; however, 50% or more of patients discontinue statin treatment within 1 year of initiation. In2015,thefirstanti-PCSK9antibodies,alirocumabandevolocumab, wereapprovedforuseinEuropeandtheUSA. [14] [15] [16] [17] Thisreviewdiscusses the implications of using these new agents in clinical practice by using data on their efficacy and safety as reported in studies previously identifiedbyoursystematicreviewofphase3studiesofanti-PCSK9anti-bodies in patients with hypercholesterolaemia.
18
Toputtheefficacydata fromphase3clinicalstudiesintothecontextofclinicalpractice,hypotheticalcasestudiesarediscussed,togetherwithsafetydatafromLLTs.
| METHODS
The previous systematic review identified 12 phase 3 studies of alirocumab and 9 phase 3 studies of evolocumab, together includingmore than 10000 patients with elevated cholesterol levels(and hence, increased CV risk). 18 Additional references were identified fromnon-systematicliteraturesearches.Nohead-to-headtrialshave compared the efficacy and safety of alirocumab and evolocumab.
Therefore, the current review used data from the identified studies toanalysereductionsinLDL-C,ratesofLDL-Cgoalachievementand ratesofadverseevents(AEs).Asameasureoftheefficacyofthese agentsinclinicalpractice,wecalculatedthenumberneededtotreat (NNT),usingthefollowingformula
wheren=LDL-Creductioninmmol/LandXrepresentsthehazardratio ofCVEriskforeach1mmol/LreductioninLDL-C.
5
Number needed to treat values were rounded up to the nearest whole figure to avoid overestimating effectiveness. 20 In a large meta-analysisofdatafromclinicaltrialsofstatins(withafollow-upof 5years),theCholesterolTreatmentTrialists'(CTT)collaborationestimatedthatX,thehazardratioofCVEriskforeach1mmol/Lreduction inLDL-C,tobe0.78. ; a follow-up periodof 10yearswasused in the our paper.WhenconsideringtheNNTestimatesinourpaper,itisimportanttonotethat thepopulationsincludedintheCTTanalysisdifferslightlyfromthose enrolled in the anti-PCSK9 trials. Moreover, the recently published FOURIER study provides evidence for a delay in the onset of risk reduction with evolocumab. 26 Hence,theNNTestimationspresented
here may be overestimated.
| RESULTS

| LDL-C reductions with alirocumab and evolocumab in different patient populations
Among patients with hypercholesterolaemia or mixed dyslipidaemia, rapid (within 1-2weeks) and persistent (20-74weeks with alirocumab [27] [28] [29] [30] [31] [32] [33] [34] [35] and 8-38weeks with evolocumab [36] [37] [38] [39] [40] [41] [42] ) reductions in LDL-C and total cholesterol, compared with the control arms of clinicaltrials,wereachievedwithalirocumabandevolocumab.
18
The LDL-C reductions in patients with hypercholesterolaemia or mixed dyslipidaemia with alirocumab or evolocumab monotherapy were 51 How these data will translate into clinical practice is under debate; less than half of patients had not exhausted all statin options before enrolling in the study and apheresis was stopped once patients' LDL-C levels were at least 30% lower than at preapheresisbaseline,whichmaynotbesufficienttoachieveLDL-Cgoal amongpatientsveryhighLDL-Clevelsatbaseline.
52
Notwithstanding,
German reimbursement rules currently in place require initiation of anti-PCSK9 antibodies before approval of apheresis treatment. This islegitimatesincePCSK9inhibitionmayresultinimprovedqualityof life at significantly lower costs compared with apheresis.
48
A phase 3 randomised study assessing evolocumab compared with apheresis in patients with hypercholesterolaemia who were already receiving LDL-Capheresisisongoing(NCT02585895).
| LDL-C goal achievement with alirocumab and evolocumab in different patient populations
In the included studies, goal achievement was measured according T A B L E 1 (Continued)
and3.7%,respectively)andthatarthralgiaoccurredin5.1%and4.8%
ofpatients,respectively(placeboorstandardofcare:6.5%and3.2%, respectively).
58,59
Although there is somevariation in the incidences ofmuscle-relatedAEsreportedintrialsofanti-PCSK9antibodies,in general these are balanced between study arms. In the pooled anal- Inapooledanalysisoftwoopen-label randomised trials (OSLER-1 and OSLER-2), the incidences of neurocognitive events in patients treated with evolocumab plus standard therapyversusstandardtherapyalonewere0.9%and0.3%,respectively, at week 48.
41
No association has been found between the rateoftheseAEsandLDL-Creductioninthisorotherstudies. 33, 41, 59 However, a recent meta-analysis of 13083 patients in phase 2 and
3trialsreportedthatanti-PCSK9antibodieswereassociatedwithan increased incidence of neurocognitive AEs compared with placebo (odds ratio [OR] 2.34; P=.02).
63
This meta-analysiswas based on 55 neurocognitive events and resulted in a number needed to harm of
to 3257. 64 The methodology of this meta-analysis was criticised as somepatientswerecountedmorethanonce,owingtotheirparticipationinboththeOSLERstudiesandtheparentstudies. of those receiving the standard of care.
41,59
Limiteddataareavailableontheuseofanti-PCSK9antibodiesin patientswithhepaticorrenalimpairment.However,anti-PCSK9anti-bodies are proteins and are therefore not expected to be metabolised by the liver or kidneys; hence, no effects on the liver or kidneys are expected. For evolocumab, a small pharmacokinetics study reported no differences in efficacy or safety between healthy volunteers and in patients with mild or moderate hepatic impairment. 66 Anotherevolocumab study reported no differences in LDL-C lowering or safety among patients with normal renal function and those with severe renalimpairmentorend-stagerenaldisease.
67
Therecentlypublished FOURIER study included patients with renal impairment (glomerular filtrationrateaslowas20mL/min) 26 and subgroup analyses examining the safety and efficacy of evolocumab in this population are expected.
For alirocumab, a pooled analysis of data from patients with type 2 diabetes mellitus and chronic kidney disease enrolled in phase 3 trialsshowednodifferenceinLDL-Cloweringorsafetysignalsbetween patientswithmildormoderatekidneydisease.Furthermore,noeffect on chronic kidney disease progression was observed.
68
Althoughlarger studiesinpatientswithhepaticorrenalimpairmentarewarranted,current evidence supports the use of evolocumab without dose adjustments in these patients. 15 Similarly,withalirocumab,doseadjustments arenotrequiredforpatientswithrenalorhepaticimpairment,although no data are currently available for patients with hepatic impairment.
17
The systematic review of phase 3 data for alirocumab and evolocumabreportedthat,asidefrommusculoskeletalevents,themost commonAEswerenasopharyngitisandupperrespiratorytractinfections.
18
Injectionsitereactionswerereportedatsimilarfrequenciesin evolocumabandcontroltreatmentarms,whilststudiesofalirocumab varied in whether injection site reactions occurred more often with the anti-PCSK9 agent or comparators. 18 Treatment-emergent antidrugantibodieswererare,butwerereportedinfivealirocumabstudies(highestincidence12%),andinonepatientinasingleevolocumab study.
Treatment-emergentneutralisingantibodieswerereportedin asmallnumberofpatients(<1%)infourofthealirocumabstudiesthat wereincludedintheanti-PCSK9systematicreview,butthisdidnot impact on efficacy or safety. 18 Of the evolocumab studies that assessed the formation of neutralising antibodies, such antibodies were not detected in any patient receiving evolocumab.
Furthermore,noneutralising antibodies were detected in the pooled analysis of over 6000 patients who had participated in evolocumab clinical trials. 59 
Serious
AEs, treatment-related discontinuations and discontinuations owing toAEswererarewithanti-PCSK9antibodytherapy. 18 Importantly,nosignificantdifferencesintheincidenceAEs,both overall and within each category of AE were observed in patients achievingverylowlevelsofLDL-CandthosewithhigherLDL-Clevels with evolocumab 69 or with alirocumab. 
| What benefits can be expected when using anti-PCSK9 antibodies?
ThereisconsiderableevidenceforacausalrelationshipbetweenLDL-C reductionandadecreaseinthenumberofCVEs.
71
ThereductioninCV riskmay,however,bespecifictothemechanismofactionofadrug:
agents that increase the number of LDL receptors, such as statins, anti-PCSK9 antibodies and ezetimibe, are likely to reduce CV risk. In2005,theCTT'scollaborationpublishedameta-analysisinwhich data from over 90 000 patients were analysed to assess the effect of statintherapyonCVriskreduction.
75
Anupdatetothismeta-analysis assessing the impact of more or less intensive statin therapy was published in 2010. 5 Both studies found that a 40mg/dL (1mmol/L) reductioninLDL-CreducedtheannualrateofmajorCVEsbyapproximatelyafifth(21%inthe2005studyand22%inthelaterstudy).
5,75
Crucially,the2010meta-analysisdemonstratedthat,withinthecholesterolrangestudied,thesizeoftheproportionalreductioninmajorCVEs was directly proportional to the absolute LDL reduction achieved. It was suggestedthatreducingLDL-Cby80-120mg/dL(2-3mmol/L;asseen with anti-PCSK9 antibodies) would reduce risk by 40%-50%.
5
More recently, the double-blind, randomised IMPROVE-IT trial compared CVEsby7.9%.
5,75
ThiscurrentstudyhasdemonstratedthataddingLLTs tostatinscanreducetheriskofCVEs,consistentwiththeconclusion of the CTT meta-analysis.
The nature of the relationship between intensiveLDL-CloweringandCVErateswarrantsfurtherinvestigation.
TheloweringofLDL-Cachievedwithanti-PCSK9antibodyther-apy may also reduce CV risk. Over periods of ayear or more, alirocumab or evolocumab have been reported to signficantly reduce the rateofCVEswhenaddedtostandardtherapy(Table2).
33,41
Although these studies were not designed or powered to examine efficacy in termsofCVbenefit,itisinterestingtoobservethatthereductionsin incidenceofCVEswithanti-PCSK9antibodytherapyfitwellwiththe-oreticalreductionspredictedonthebasisofdatafromtheCTTmetaanalysis.
5,75
Based on a predicted reduction in CVE rate of 22% for 
26
T A B L E 3 Predicted10-yearNNTwithananti-PCSK9antibody(withapredicted60%LDL-Creductionfrombaseline)toprevent1CVEfor variousabsolute10-yearriskofmajorCVEsandvariousbaselineLDL-Clevels PatientsmayormaynotbereceivingLLT.
b UsingdatafromtheCTTmeta-analysis. Heartfailure(NewYorkHeartAssociationclassificationIII-IV) CVD, cardiovascular disease; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9, proprotein convertase subtilisin/kexin type 9.
| Hypothetical patient cases
Wehaveusedthehypotheticalprinciplesofanti-PCSK9antibody-mediated LDL-C lowering (assuming that the same benefit is observedaswithstatinandezetimibe)topredict10-yearNNTswith anti-PCSK9 antibodies to prevent one CVE for patients with varyingbaselineLDL-Clevelsandabsolute10-yearCVErisks(Figure2).
As the 10-year risk of a CVE increased, the NNT to prevent one T A B L E 5 Predictedoutcomesinahypotheticalcaseofa54-yearoldmalepatientwhohadpreviouslyexperiencedamyocardialinfarction andhasveryhighbaselineLDL-Clevels(scenarioA)despitereceivingmaximallytoleratedstatinplusezetimibeand(scenarioB)under ezetimibetreatmentinthescenarioofstatinintolerance. OnthebasisoftheoverallresultsfromODYSSEYCOMBOII, 28 anabsolutereductioninLDL-Clevelsofatleast100mg/dL(2.6mmol/L)would beanticipatedinscenarioAfollowingtheadditionofananti-PCSK9antibodytoastatinplusezetimibe.UsingestimatesfromtheCTTtrial,this wouldtranslateintoa47%reductioninrelativeriskofmajorCVEsover10years. ezetimibeslightlyreducedthe10-yearabsoluteriskofCVdeathfrom20%to17%;treatmentwithanti-PCSK9antibodieswas predictedtodrasticallyreducethisriskto8%(areductioninpredictedabsolute10-yearriskofaCVEfrom60%to24%).TheNNTforthe additionofananti-PCSK9antibodytoezetemibetherapywas4,comparedwith10withezetimibealone.Inbothscenarios,itwasassumedthat treatments were well tolerated and that patients were adherent to treatment 
| CONCLUSIONS AND CLINICAL IMPLICATIONS
Anti-PCSK9antibodiesaresafe,welltoleratedandefficaciousinloweringLDL-Cinabroadrangeofpatientpopulations,andaresuitable F I G U R E 3 PredictedLDL-Creductions andcorrespondingCVriskthatmaybe expected when using a statin and then an anti-PCSK9antibodyasanadd-ontherapy inapatientwitha10-yearabsoluteriskof amajorCVEof60%:ahypotheticalcase example of a male patient aged 54 years who has experienced a previous myocardial infarction.CV,cardiovascular;CVE, cardiovascularevent;LDL-C,low-density lipoproteincholesterol;PCSK9,proprotein convertase subtilisin/kexin type 9 as an add-on therapy to a statin or ezetimibe, or as a monotherapy forpatientswhoareintoleranttostatins.Currentdatasuggestthat theynotonlylowerLDL-C,butalsoreducetheriskofCVEs.Studies that look at CV outcomes as a primary end-point are ongoing, and long-termdatafromoutcomestudiesareawaited.Theseanti-PCSK9
antibodies are currently costly as they are intended for only a narrow population;however,onceCVoutcomesdataareavailabletheindication may expand and costs may therefore decrease. In Germany, theannualcostfortreatingonepatientperyearwithananti-PCSK9 antibodyisapproximately€8500.
76
Therefore,theuseofanti-PCSK9 antibodies may be limited by payers to patients with an extremely highCVriskandhighLDL-ClevelsafterexhaustingallotherLLTsat maximally tolerated doses (Table4).
According to this reasoning, approximately60000patientswouldbeeligibleforanti-PCSK9anti-bodytreatmentinGermany. andhasbeenemployedbySynlabHoldingDeutschlandGmbH.
